NewAmsterdam Pharma Company N.V./$NAMS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
- Ticker
- $NAMS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 100
- Headquarters
- Naarden, Netherlands
- Website
- www.newamsterdampharma.com
NAMS Metrics
BasicAdvanced
$2.4B
-
-$2.14
0.11
-
Price and volume
Market cap
$2.4B
Beta
0.11
52-week high
$42.21
52-week low
$19.13
Average daily volume
1.6M
Financial strength
Current ratio
9.033
Quick ratio
8.759
Long term debt to equity
0
Total debt to equity
0
Profitability
EBITDA (TTM)
-244.163
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-3,644.21%
Operating margin (TTM)
-3,432.20%
Revenue per employee (TTM)
$70,000
Management effectiveness
Return on assets (TTM)
-20.11%
Return on equity (TTM)
-36.81%
Valuation
Price to revenue (TTM)
340.93
Price to book
3.74
Price to tangible book (TTM)
3.74
Price to free cash flow (TTM)
-16.892
Free cash flow yield (TTM)
-5.92%
Free cash flow per share (TTM)
-1.188
Growth
Revenue change (TTM)
-88.87%
Earnings per share change (TTM)
38.74%
3-year revenue growth (CAGR)
-13.40%
3-year earnings per share growth (CAGR)
-18.02%
What the Analysts think about NAMS
Analyst ratings (Buy, Hold, Sell) for NewAmsterdam Pharma Company N.V. stock.
Analyst projections of the future price of NewAmsterdam Pharma Company N.V. stock.
Bulls say / Bears say
The European Commission has approved obicetrapib alone and with ezetimibe, giving NewAmsterdam its first authorised product and opening a route to European sales. (NewAmsterdam Pharma)
Phase 3 studies showed LDL cholesterol reductions of up to 40% with obicetrapib alone and about 50% with ezetimibe, with tolerability comparable to placebo. That could make the oral treatment useful for patients who need more LDL lowering or do not tolerate existing options. (NewAmsterdam Pharma)
A Phase 3 analysis found a statistically significant reduction in an Alzheimer’s disease biomarker, and the company has begun a 400-participant Phase 2b study. If confirmed in dedicated trials, this could extend obicetrapib’s potential beyond cholesterol treatment. (NewAmsterdam Pharma)
The key test of whether obicetrapib prevents heart attacks and strokes is still pending: the 9,500-patient PREVAIL trial is due for an interim readout in 2027. Earlier LDL-lowering results do not yet establish a cardiovascular benefit. (NewAmsterdam Pharma)
The company remains loss-making while preparing for commercialisation: second-quarter revenue was $3.7 million against a $64.1 million net loss, and cash and marketable securities were $678.3 million at June 2026. Continued trial and launch spending could consume that funding before product revenue scales. (NewAmsterdam Pharma)
NewAmsterdam has licensed European commercialisation exclusively to Menarini, so it relies on its partner to build sales in the region and receives royalties rather than keeping the full product economics. The deal offers potential milestone payments, but those depend on future clinical, regulatory and commercial achievements. (NewAmsterdam Pharma)
Data summarised monthly by Lightyear AI. Last updated on 23 Oct 2026.
NAMS Financial Performance
Revenues and expenses
NAMS Earnings Performance
Company profitability
Upcoming events
No upcoming events
NAMS News
AllArticlesVideos
Funds containing NAMS
Fund name | Fund size | $NAMS weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.15% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.15% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $3.2B | 0.02% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | $3.2B | 0.02% |
Xtrackers MSCI World Small Cap$XSWC | $183M | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.